A new study finds that more than 200 human-targeted, non-antibiotic drugs inhibit the growth of bacterial species that make up part of the human microbiome.
Phage therapy is but one example of using biological entities to reduce our reliance on antibiotics and other failing chemical solutions.
July 17, 2017|
ISLAND PRESS, JUNE 2017This year I gave a presentation to public-health students at a university about options for controlling pests and pathogens that didn’t depend on industrial-age chemicals such as antibiotics and pesticides. When I asked if they’d ever heard of phage therapy—the use of bacteria-attacking viruses to fight infection—I was met with blank stares. When I finished sharing stories of desperate patients miraculously cured of antibiotic-resistant infections within days, I sensed a bit of skepticism, as if the crowd’s politeness was keeping them from asking: “If it’s so effective, how come we’ve never heard of this?” In this age of alternate truths and quack cures, it’s an appropriate question.
But phage therapy is nothing new, nor is it some fringe remedy. It was first used to cure Shigella infections early in the 20th century, to miraculous effect (although at the time, scientists were unaware of the nature of viruses). Once treated with phages isolated from fecal samples of spontaneously recovering dysentery sufferers, patients’ Shigella-induced fevers and bloody stools subsided within 24 hours. (See “Viral Soldiers,” The Scientist, January 2016.) Within a decade, pharmaceutical companies on both sides of the Atlantic began developing various phage therapies. But then came antibiotics. And poor production practices by some pharmaceutical companies (some commercial products in the U.S. were found to be lacking in potency, for example) led to a couple of damning reviews of phage therapy in the Journal of the American Medical Association. All of this helped to close the door on phage therapy in Western medicine. The Cold War kept that door closed for decades to come.
Meanwhile, Russia, France, and Poland continued refining the therapy. Noticing the bacterial propensity to evolve resistance under pressure from killer viruses, researchers understood that they could capitalize on the even greater capacity of viruses for rapid evolution, updating phage cocktails as newly resistant bacterial strains emerged. The Phage Therapy Center in Tbilisi, Georgia, currently offers phage treatments.
Despite encountering skepticism about the effectiveness of phage therapy, I have also been asked by students desperate to find a cure for themselves, or a loved one, to recommend phage-friendly doctors here in the U.S. Other than suggesting that they ask their physician to look into phage therapies or do a Google search, I have had little to offer. But there are glimmers of hope. Now, Western scientists and physicians are trying to introduce the therapy into the American pharmacopeia. In July 2015, the National Institutes of Health organized a meeting of international bacteriophage scientists, entrepreneurs, and regulators hailing from the United States, France, Georgia, China, and elsewhere. Another workshop will be held this July in Rockville, Maryland. There are now clinical trials of phage-therapy products underway in the U.S. and in Europe. If successful, developers will soon be knocking on the FDA’s door.
Phage therapy is just one example of a disease-control approach that is more in tune with nature, whether we are concerned about protecting our kids or a field of strawberries. In my new book Natural Defense: Enlisting Bugs and Germs to Protect Our Food and Health, I explore a range of strategies that can help us reduce our dependence on chemicals, from antibiotics to pesticides. The control of microbial infections in humans, in particular, shares many characteristics with agricultural strategies. Rapid, more-accurate diagnostics will help both in the hospital and on the farm: new technological solutions promise to enable rapid disease detection and identification. Prevention can help protect us and the crops we grow. And sometimes the solutions in field and body are the same—phages are useful allies against bacteria in the food industry and in human medicine. As I write in the preface, these are just a few strategies. Some may work, others may not, but such combined efforts can help to reduce our dependence on 20th-century chemical cures. For too long, we have considered ourselves separate from the environment. But the sooner we begin working with, rather than against, nature for our food and health, the better off we will be.
Emily Monosson is an environmental toxicologist. She is an independent scholar at the Ronin Institute and an adjunct professor at the University of Massachusetts, Amherst. Read an excerpt of Natural Defenses.
Correction (July 17): The original version of this article indicated that Shigella was a virus. It is, of course, a species of bacteria. The Scientist regrets the error.
July 17, 2017
I would suggest that we keep focusing too much on the science and redoing the same thing like running to rivers and isolating new phages. To my mind it is time to start treating patients, keeping in mind that in many countries the treatment is legally available under special legal provisions. I believe we need to more often include legal, moral and ethical considerations when discussing phage therapy - is it morally and ethically defensible to withhold phage therapy from patients for whom we have nothing else to offer (antibiotic-resistant superbug infections)? This, to my mind, applies especially to hospital acquired infections. I believe it should be the hospitals responsibility to inform the patient of this treatment option; however, in far too many cases in the past patients or their relatives have brought information on phage therapy to the doctors when phage therapy has been used - surely patients should be offered the right to try?
Thinking about the above statement made me think that some countries have charters of rights for citizens and it seems to me that provisions such as 'right to life and liberty' would make a good case with reference to phage therapy - alas it would require patient organizations that are concerned about the increasing failure of antibiotics and superbug infections and consequences. To my knowledge there are few such organizations.
July 17, 2017
A considerable amount of progress in phage-based products have occured in the last decade. A Baltimore company, Intralytix, is commercially selling phage-based food safety cocktails effective against Listeria monocytogenes, E. coli 0157:H7 and Salmonella spp. All have been approved by U.S., Canadian and Israeli regulators. Most recently, Intralytix's shigella formulation has been recognized by U.S. regulators as GRAS, which should expedite its commercial use.
July 19, 2017
This further adds to the absurdity of our attitude towards phage therapy - if it is o.k. to use it to kill bacteria in foods, it should be available to treat patients when antibiotics fail. and I am convinced some folks at Intralytix agree with me.
July 25, 2017
Although not that new, still this topic is very much interesting. We are publishing a Newsletter in Medical Microbiology form Bangladesh. It has got a segment named "Innovation". We like to add a brief paragraph on your title- Bacteriphages to rescue. Comment please!